MySense.ai Competitors

At IBM, we do more than work. We create. We create as technologists, developers, and engineers. We create with our partners. We create with our competitors. If you're searching for ways to make the world work better through technology and infrastructure, software and consulting, then we want to work with you. We're here to help every creator turn their "what if" into what is. Let's create something that will change everything.

Founded in 2014, SenseTime is a leading artificial intelligence (AI) software company, committed to its mission of "creating a better AI-empowered future through original innovation". The Company continues to lead cutting-edge AI research while accelerating the large-scale commercialisation of AI technologies. Leveraging deep academic expertise and strong in-house innovation capabilities, SenseTime continues to enhance its industry-leading multimodal, multi-task general AI capabilities, while fostering a vibrant developer ecosystem through structured open-source initiatives. SenseTime's business spans Generative AI, Vision AI, and emerging innovation-driven segments. Underpinned by SenseCore, its next-generation AI infrastructure, the Company integrates computing power, algorithms, and platforms to enable scalable AI deployment. Building on this foundation, SenseTime has developed the SenseNova foundation model series, delivering cost-efficient capabilities across a wide range of general AI tasks. SenseTime continues to lead the global Vision AI market, ranking No.1 worldwide by market share. Its SenseFoundry platform integrates years of accumulated computer vision expertise with advanced multimodal foundation models, providing stable and efficient Vision AI solutions to industries worldwide. SenseTime is listed on The Stock Exchange of Hong Kong, with operations spanning more than a dozen countries and regions.

Freenome is a high-growth biotech company on a mission since 2014 to create tools that empower everyone to prevent, detect, and treat their disease. To achieve this mission, Freenome is developing next-generation blood tests to detect cancer in its earliest, most treatable stages using our multiomics platform and machine learning techniques. Our first blood test will detect early-stage colorectal cancer and advanced adenomas. We have raised more than $1.1 billion from leading investors like Perceptive Advisors, RA Capital Management, Roche Venture Fund, Kaiser Permanente, Novartis and the American Cancer Society’s BrightEdge Ventures. A ‘Freenomer’ is a mission-driven employee who is fueled by the opportunity to make a positive impact on patients' lives, who thrives in a culture of respect and cross collaboration, and whose work makes a significant impact on the company and their career.